Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketotifen nasal spray dose-ranging trial in rhinitis
2026-525419-16-00Phase 2Authorised
- Sponsor
- Eudemus Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ketotifen and sodium cromoglycate in rhinitis, allergic rhinitis (AR) and non-allergic rhinitis (NAR) (4 arms), sponsored by Eudemus Pharmaceuticals. Primary endpoint: Change in VAS score in the patient symptom sum score at week 12 from baseline. Planned start Jul 2026; status: authorised.
02
Drugs
ketotifensodium cromoglycate
03
Conditions
rhinitisallergic rhinitis (AR)non-allergic rhinitis (NAR)
Beyond the preview
Go deeper on 2026-525419-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525419-16-00.